Juul Faces Market Withdrawal in the US: Implications and Controversies

Jul.08.2022
Juul Faces Market Withdrawal in the US: Implications and Controversies
The FDA ordered Juul products to be removed from the US market due to concerns over youth vaping.

On June 23, the US Food and Drug Administration (FDA) announced that all Juul products must be removed from the US market. This decision significantly expanded the existing ban on the company's nicotine e-cigarettes among teenagers to include adults as well. The following day, Juul appealed to the federal court to temporarily halt the ban and questioned the decision. The court agreed to temporarily suspend the ban, and currently, Juul products are still being sold in the US.


Lynn Kozlowski, a professor at the State University of New York at Buffalo's School of Public Health and Health Professions, has been researching nicotine and tobacco addiction for several decades. In this Q&A, he addresses the recent controversy surrounding Juul products and how they fit into broader discussions among adults and young people about e-cigarettes, tobacco use, and public health.


Why does the US Food and Drug Administration want to stop the sale of Juul products?


According to the FDA, the decision to remove certain flavored electronic cigarette products from the market is a preventative measure due to the lack of "sufficient evidence of product toxicology profiles" to ensure public health and safety. The FDA also noted that it has not received any information indicating that Juul products pose an imminent danger.


In a statement, FDA Commissioner Robert M. Califf addressed the impact of Juul products on youth e-cigarette use. This decision comes as some are hoping for new bans on Juul products and other adult e-cigarettes, in effort to decrease teen e-cigarette usage.


How do the health risks of electronic cigarettes compare to traditional smoking?


At least half of smokers die prematurely due to cancer, obstructive lung disease and cardiovascular diseases caused by smoking, which shorten their average lifespan by 10 years.


Currently, there is a lack of long-term epidemiological data on e-cigarettes. However, assessments conducted in the United States and the United Kingdom have concluded that while the harm from e-cigarettes may be much less than that of traditional cigarettes, they still pose some risks. Potential hazards include nicotine addiction and some cardiovascular risks, although it is estimated that these risks are lower than those associated with smoking cigarettes.


Can electronic cigarettes reduce the harm caused by traditional smoking?


I do not encourage anyone to vape if they do not need to. However, if someone smokes and e-cigarettes help them quit completely, they can be a useful tool in reducing smoking and health issues. Quitting smoking is indisputably good for your health. Research shows that if someone quits smoking before the age of 40, they can avoid 90% of their risk of death compared to continuing to smoke. If someone quits smoking before the age of 30, their health risks are almost the same as someone who has never smoked.


The Centers for Disease Control and Prevention states that there is limited evidence to suggest that e-cigarettes aid in smoking cessation. The U.S. Food and Drug Administration has approved some e-cigarettes for sale, noting that they can be a beneficial tool for smokers in significantly reducing their tobacco use or quitting altogether.


Recent research has shown that electronic cigarettes are more effective in aiding smokers to quit than nicotine replacement therapy. The UK National Health Service has approved electronic cigarettes as a recognized form of smoking cessation aid.


Is vaping still popular among teenagers as it was before?


Teen e-cigarette use is on the decline, according to data from the Centers for Disease Control and Prevention. In 2019, 27.5 percent of high school students reported having used e-cigarettes within the past month. That number dropped to 19.6 percent by 2020, and again to 11.3 percent by 2022. Just over a quarter of monthly users, or roughly 3 percent of high schoolers in 2022, reported using e-cigarettes daily.


Some of the reduction may be due to COVID-19, restrictions on young people's access, and government anti-vaping campaigns.


The widespread publicity around the serious respiratory illness caused by e-cigarettes, known as EVALI, is likely to deter many people from using them. However, research has ultimately shown that the illness is primarily caused by illicit THC-containing e-cigarette products sold on the black market.


Will teenagers who vape lead to a higher smoking rate among adolescents?


Although the decrease in teen e-cigarette use is encouraging, an important question worth asking is whether e-cigarettes directly lead to smoking later on.


Parents have valid reasons to be concerned that e-cigarettes may serve as a gateway to smoking. However, research does not necessarily support this strong causal relationship. Despite the recent surge in e-cigarette use across the country, smoking rates have actually decreased.


According to data from a national survey of nearly 40,000 participants in the US over the past few years, researchers have found that less than 1% of those who tried e-cigarettes for the first time became long-term smokers. Compared to those who first tried cigarettes or other tobacco products, people who first tried e-cigarettes were also less likely to become smokers.


Another large-scale study on American youth found that once researchers controlled for general risky behavior, the history of using e-cigarettes was only moderately or insignificantly associated with increased smoking rates.


How do you balance adult usage with teenage safety?


Even though e-cigarettes are not a major factor contributing to youth smoking, the use of e-cigarette products by young people is still a cause for concern, despite the ban on selling e-cigarettes to those under the age of 21 in 2019.


Completely banning products that may be helpful for adult smokers who want to quit is not the only way to reduce young people's access to these services. As an example, a proposal suggests moving the sales of all nicotine and tobacco products to stores that only allow entry for individuals of 21 years or older.


While products like Juul deserve research and regulation, it is important to remember the established deadline for verification and the ease of access for cigarettes - whether it is for adults or the many teenagers who start smoking every year and will become adult smokers. Persuading as many smokers to quit as possible will save lives.


This article contains excerpts or reprints from third-party sources, and the copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any unit or individual who needs to reprint must contact the author, and direct reprinting is prohibited.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07